Neurology and Neurosurgery - Global Neurology Academy

113-128 of 481

The Future of MS Management: Novel Agents and Clinical Approaches
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiers
The Future of MS Management: Novel Agents and Clinical Approaches
Marisa McGinley, DO
- Marisa McGinley, DO
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
NeuroFrontiers
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
NeuroFrontiers
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
Modern MS Care: Navigating Treatment Options for Better Patient Outcomes
Modern MS Care: Navigating Treatment Options for Better Patient Outcomes
NeuroFrontiers
Modern MS Care: Navigating Treatment Options for Better Patient Outcomes
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
NeuroFrontiers
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
NeuroFrontiers
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
NeuroFrontiers
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
David Gate, PhD
- David Gate, PhD
Advancing MS Care: Evolving Treatments and High-Efficacy Approaches
Advancing MS Care: Evolving Treatments and High-Efficacy Approaches
NeuroFrontiers
Advancing MS Care: Evolving Treatments and High-Efficacy Approaches
Marisa McGinley, DO
- Marisa McGinley, DO
Understanding MS: Managing Hidden and Overlooked Symptoms
Understanding MS: Managing Hidden and Overlooked Symptoms
Global Neurology Academy
Understanding MS: Managing Hidden and Overlooked Symptoms
Marisa McGinley, DO
- Marisa McGinley, DO
Recognizing the Full Spectrum of MS Symptoms: Multidisciplinary Pathways to Better Care
Recognizing the Full Spectrum of MS Symptoms: Multidisciplinary Pathways to Better Care
NeuroFrontiers
Recognizing the Full Spectrum of MS Symptoms: Multidisciplinary Pathways to Better Care
Marisa McGinley, DO
- Marisa McGinley, DO
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
NeuroFrontiers
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
NeuroFrontiers
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
NeuroFrontiers
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
Early Evidence Supports Videoconference ACT for Dementia Caregivers with Depression
Early Evidence Supports Videoconference ACT for Dementia Caregivers with Depression
NeuroFrontiers
Early Evidence Supports Videoconference ACT for Dementia Caregivers with Depression
Restoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
Restoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
NeuroFrontiers
Restoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
NeuroFrontiers
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial

Previous
1
2
…
6
7
8
9
10
…
30
31
Next

8/11